JP2025500483A5 - - Google Patents
Info
- Publication number
- JP2025500483A5 JP2025500483A5 JP2024538263A JP2024538263A JP2025500483A5 JP 2025500483 A5 JP2025500483 A5 JP 2025500483A5 JP 2024538263 A JP2024538263 A JP 2024538263A JP 2024538263 A JP2024538263 A JP 2024538263A JP 2025500483 A5 JP2025500483 A5 JP 2025500483A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- hvr
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163292863P | 2021-12-22 | 2021-12-22 | |
| US63/292,863 | 2021-12-22 | ||
| US202263383451P | 2022-11-11 | 2022-11-11 | |
| US63/383,451 | 2022-11-11 | ||
| US202263387229P | 2022-12-13 | 2022-12-13 | |
| US63/387,229 | 2022-12-13 | ||
| PCT/US2022/082139 WO2023122665A1 (en) | 2021-12-22 | 2022-12-21 | Clinical formulations of anti-tigit antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025500483A JP2025500483A (ja) | 2025-01-09 |
| JP2025500483A5 true JP2025500483A5 (cg-RX-API-DMAC7.html) | 2025-12-24 |
Family
ID=85199491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024538263A Pending JP2025500483A (ja) | 2021-12-22 | 2022-12-21 | 抗ｔｉｇｉｔ抗体の臨床製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240408009A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4452320A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025500483A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240121771A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022417501A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242136A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL313658A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024007749A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202330034A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023122665A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202515614A (zh) | 2023-08-25 | 2025-04-16 | 美商建南德克公司 | 治療非小細胞肺癌之方法及組成物 |
| WO2025174933A1 (en) | 2024-02-14 | 2025-08-21 | Genentech, Inc. | Methods for treatment of pancreatic cancer with anti-pd-l1 ab, anti-tigit ab, gemcitabine and nab-placlitaxel |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| KR20220113414A (ko) | 2019-12-09 | 2022-08-12 | 제넨테크, 인크. | 항-pd-l1 항체 제제 |
| CN115052622B (zh) * | 2020-01-21 | 2026-03-06 | 夏尔巴生物技术(杭州)有限公司 | 重组全人源抗tigit单克隆抗体制剂及其制备方法和用途 |
| TW202142230A (zh) * | 2020-01-27 | 2021-11-16 | 美商建南德克公司 | 用於以抗ｔｉｇｉｔ拮抗體抗體治療癌症之方法 |
-
2022
- 2022-12-21 AU AU2022417501A patent/AU2022417501A1/en active Pending
- 2022-12-21 CA CA3242136A patent/CA3242136A1/en active Pending
- 2022-12-21 JP JP2024538263A patent/JP2025500483A/ja active Pending
- 2022-12-21 EP EP22854694.1A patent/EP4452320A1/en active Pending
- 2022-12-21 IL IL313658A patent/IL313658A/en unknown
- 2022-12-21 MX MX2024007749A patent/MX2024007749A/es unknown
- 2022-12-21 WO PCT/US2022/082139 patent/WO2023122665A1/en not_active Ceased
- 2022-12-21 KR KR1020247021095A patent/KR20240121771A/ko active Pending
- 2022-12-22 TW TW111149551A patent/TW202330034A/zh unknown
-
2024
- 2024-06-20 US US18/749,129 patent/US20240408009A1/en active Pending